amsacrine ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
acridine derivatives 203 51264-14-3

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • amsacrine
  • acridinylanisidide
  • amekrin
  • amsidil
  • amsidine
  • amsidyl
  • lamasine
An aminoacridine derivative that intercalates into DNA and is used as an antineoplastic agent.
  • Molecular weight: 393.46
  • Formula: C21H19N3O3S
  • CLOGP: 4.54
  • LIPINSKI: 0
  • HAC: 6
  • HDO: 2
  • TPSA: 80.32
  • ALOGS: -5.09
  • ROTB: 4

Drug dosage:

None

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 10 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 10.05 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution) 1.60 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 4.30 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.03 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 4.70 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Jan. 1, 1987 YEAR INTRODUCED

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Acute myeloid leukaemia recurrent 85.91 70.37 14 399 1376 50603335
Graft versus host disease 76.55 70.37 16 397 6150 50598561
Systemic inflammatory response syndrome 73.77 70.37 15 398 5034 50599677

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Acute myeloid leukaemia recurrent 124.66 113.06 21 329 1759 29572418

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Acute myeloid leukaemia recurrent 164.21 69.37 28 664 2756 64495284
Venoocclusive liver disease 122.85 69.37 27 665 9988 64488052

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01XX01 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
OTHER ANTINEOPLASTIC AGENTS
Other antineoplastic agents
CHEBI has role CHEBI:35610 antineoplastic agents
CHEBI has role CHEBI:50750 inhibitors of type II topoisomerase
MeSH PA D000970 Antineoplastic Agents
MeSH PA D007202 Indicators and Reagents
MeSH PA D007364 Intercalating Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

None




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.98 acidic
pKa2 8.25 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
DNA topoisomerase II Enzyme EC50 6.14 CHEMBL
Potassium voltage-gated channel subfamily H member 2 Ion channel IC50 6.68 CHEMBL
Cytochrome P450 2D6 Enzyme Ki 5.12 WOMBAT-PK
DNA topoisomerase 2-alpha Enzyme IC50 5 CHEMBL
DNA topoisomerase I, mitochondrial Enzyme IC50 7.43 WOMBAT-PK
DNA topoisomerase 1 Enzyme IC50 7.43 WOMBAT-PK
DNA topoisomerase 2-beta Enzyme EC50 4.96 CHEMBL
Solute carrier family 22 member 1 Transporter IC50 5.30 CHEMBL

External reference:

IDSource
4025233 VUID
N0000171765 NUI
D02321 KEGG_DRUG
151347 RXNORM
C0002699 UMLSCUI
CHEBI:2687 CHEBI
ASW PDB_CHEM_ID
CHEMBL43 ChEMBL_ID
DB00276 DRUGBANK_ID
D000677 MESH_DESCRIPTOR_UI
2179 PUBCHEM_CID
4864 INN_ID
00DPD30SOY UNII
003469 NDDF
4025233 VANDF
326955000 SNOMEDCT_US
391774005 SNOMEDCT_US

Pharmaceutical products:

None